China Resources Shuanghe announced that the company, its wholly-owned subsidiary Xi'an Jingxi Shuanghe Pharmaceutical Co., Ltd., and its holding subsidiary, China Resources Shuanghexiang Chinese Pharmaceutical Co., Ltd. recently received “Drug Registration Certificates” for injectable isaconazole sulfate, sorbitol mannitol, and bryprazole tablets issued by the State Drug Administration, all of which were deemed to have passed the consistency evaluation. Injectable isaconazole sulfate is used to treat aggressive aspergillosis and invasive pilomycosis, with a total R&D investment of 164.557 million yuan; sorbitol mannitol rinsing agents are used for rinsing during urological surgery, with a total R&D investment of 3.4094 million yuan; and briprazole tablets are used to treat schizophrenia in adults, with a total R&D investment of 9.918,500 yuan. This certification will enrich the company's product line, and there is uncertainty about the drug sales situation.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.